Deadline Date: April 13, 2026
The Quarterly Research Grant Funding Programme is inviting applications to support preclinical and clinical research focused on slowing, stopping or reversing Parkinson’s.
The focus of this funding is on laboratory or clinical research that aims to prevent, slow, stop, or reverse the underlying progression of Parkinson’s disease. Priority is given to projects that demonstrate a clear path toward clinical application within five years. The programme supports clinical trials involving people with Parkinson’s, sub-studies connected to clinical trials, infrastructure projects that assist trial development, and preclinical research investigating therapies with strong potential to move into clinical trials.
The funding scheme supports both preclinical and clinical research initiatives. For preclinical research, grants of up to £250,000 (GBP) are available, with preference given to projects likely to progress into clinical trials within five years. Clinical research funding includes support for clinical trials and sub-studies involving people with Parkinson’s, and the grant amount for clinical trials is flexible.
They fund projects internationally and accept applications from academic institutions as well as commercial organisations. In commercial applications, proposed costs should be justified and should align with academic cost standards wherever possible. All applicants must comply with the grant terms and conditions outlined in the grant contract, and geopolitical, economic, or trade restrictions and sanctions may influence their ability to accept certain applications.
For more information, visit Cure Parkinson’s.
